<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427336</url>
  </required_header>
  <id_info>
    <org_study_id>IDP00-266</org_study_id>
    <nct_id>NCT00427336</nct_id>
  </id_info>
  <brief_title>Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia</brief_title>
  <official_title>Purine Analog-Based Conditioning for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        1. To determine the feasibility and toxicity of employing purine-analog based conditioning
           for allogeneic donor stem cell transplantation in patients with severe aplastic anemia
           (AA).

        2. To determine the engraftment kinetics and degree of chimerism that can be achieved with
           this strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before treatment starts, patients will have their bone marrow checked and will have lung,
      heart, and kidney tests.

      Patients in this study will receive the drugs fludarabine, cyclophosphamide, and
      antithymocyte globulin by vein through a previously inserted plastic catheter that extends
      into the large chest vein. Fludarabine will be given daily for four days, cyclophosphamide
      will given daily for four days, and antithymocyte globulin will be given daily for four days
      (three days for related donor transplants).

      Two days after the last dose of cyclophosphamide, donor marrow or stem cells will be infused
      through a catheter (thin plastic tube). Drugs will be given to lower the chance of an
      allergic reaction to the stem cells. Patients will also get shots of filgrastim (a drug that
      helps white blood cell growth) and antibiotics by mouth. The blood cell counts will fall to
      low levels during the first 2 weeks when patients may need transfusions of red blood cells
      and platelets. The chemotherapy will be given in the hospital. After the infusion of stem
      cells, patients will be monitored in the hospital. They will later be closely followed as
      outpatients and will be required to remain in the Houston area for about three months after
      the transplant.

      Drugs (cyclosporine and methotrexate) to lower the chance of graft-versus-host disease will
      be given. Cyclosporine will be given as a continuous infusion starting 2 days before
      transplantation. Methotrexate will be given through the catheter on Days 1, 3, 6 and 11 after
      transplantation. Cyclosporine will be given as pills when the patient is able to swallow.
      Cyclosporine will be continued for no less than 6 months after transplantation after which it
      will be gradually stopped. The drug tacrolimus may be used instead of cyclosporine.

      Blood, urine, bone marrow, and x-ray exams will be done as needed to monitor the results of
      bone marrow transplantation. Patients may require blood and platelet transfusions. Blood
      tests will be done daily while hospitalized and several times a week until the blood counts
      recover. Bone marrow aspiration and biopsies will be performed before the transplant, when
      the donated cells show signs of engraftment, and at other times during the next 1 to 3 years.
      They will be done to evaluate the growth of the transplant marrow, possible recurrence of
      malignancy, and recovery of immunity. If this treatment proves unsuccessful in more than
      three of the first ten patients, the study will be stopped.

      This is an investigational study. The FDA has approved all of the drugs in this study for
      other indications. Up to 30 patients will be treated on this study. All will be enrolled at
      M.D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Engraftment Response</measure>
    <time_frame>First 100 days post transplant.</time_frame>
    <description>Engraftment defined as (1) the first of three consecutive days of an Absolute neutrophil count (ANC) &gt;500/mL (b) the first of seven consecutive days of an unsupported platelet count 20,000. Patient needs to survive at least 28 days to be evaluable for engraftment. Chimerism studies need to demonstrate donor-derived hematopoiesis (&gt;90%)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Fludarabine + Cyclophosphamide + ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m^2 by vein daily over 30 minutes</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + ATG</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300 mg/m^2 by vein daily over 2 hours</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + ATG</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte Globulin</intervention_name>
    <description>3.75 mg/kg by vein daily over 4 hours</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + ATG</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients up to 70 years of age with a diagnosis of severe AA (Camitta et al., 1979)
             and a matched unrelated donor who are unresponsive to IS or who have relapsed after an
             initial response to IS. Patients with a diagnosis of SAA and an human leukocyte
             antigen (HLA) - compatible sibling donor are eligible only if they are 40 years of age
             or older (up to age 70) and regardless whether they have received IS or not. Patients
             with primary or secondary graft failure following autologous or allogeneic stem cell
             transplant are eligible.

          -  Patients must have a serum bilirubin of 2 mg/dl or less, serum creatinine &lt; 2.0 mg/dl,
             no symptomatic cardiac or pulmonary disease and a PS of no more than 2. Life
             expectancy not severely limited by concomitant illness (&gt; 12 weeks). Left ventricular
             ejection fraction &gt; 40%, no uncontrolled arrhythmia or symptomatic cardiac disease.
             Forced Expiratory Volume in 1 Second (FEV1), Forced Vital Capacity (FVC) and Carbon
             Monoxide Diffusing Capacity (DLCO) &gt; 40%. No symptomatic pulmonary disease. Negative
             pregnancy test.

          -  Patients must have an HLA-compatible related or unrelated donor willing to donate
             marrow or rhG-CSF-mobilized peripheral blood stem cells. In the event of transplants
             from matched unrelated donors, a high-resolution allele match for HLA-A, -B, -C, -DRB1
             and DQB1 (&quot;10 of 10 match&quot;) is preferred. However, a one-antigen mismatch
             (&quot;micromismatch&quot;) is also considered acceptable matching (&quot;9 of 10 match&quot;).

          -  Patients must sign informed consent. In the event of a pediatric patient (i.e., a
             minor), consent will be provided by their guardian/parent.

          -  Lack of clonal cytogenetic abnormalities associated with acute myeloid leukemia (AML),
             myelodysplastic syndrome (MDS) or other hematologic malignancies.

        Exclusion Criteria:

          -  Life expectancy of less than 8 weeks. Inability to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Anderlini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>September 20, 2011</results_first_submitted>
  <results_first_submitted_qc>September 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 27, 2011</results_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Aplastic Anemia</keyword>
  <keyword>Bone Marrow Failure</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Antithymocyte Globulin</keyword>
  <keyword>SAA</keyword>
  <keyword>ATG</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Thymoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: December 2000 to August 2009. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fludarabine + Cyclophosphamide + ATG</title>
          <description>Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fludarabine + Cyclophosphamide + ATG</title>
          <description>Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="18" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Engraftment Response</title>
        <description>Engraftment defined as (1) the first of three consecutive days of an Absolute neutrophil count (ANC) &gt;500/mL (b) the first of seven consecutive days of an unsupported platelet count 20,000. Patient needs to survive at least 28 days to be evaluable for engraftment. Chimerism studies need to demonstrate donor-derived hematopoiesis (&gt;90%)</description>
        <time_frame>First 100 days post transplant.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine + Cyclophosphamide + ATG</title>
            <description>Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Engraftment Response</title>
          <description>Engraftment defined as (1) the first of three consecutive days of an Absolute neutrophil count (ANC) &gt;500/mL (b) the first of seven consecutive days of an unsupported platelet count 20,000. Patient needs to survive at least 28 days to be evaluable for engraftment. Chimerism studies need to demonstrate donor-derived hematopoiesis (&gt;90%)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 years, 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fludarabine + Cyclophosphamide + ATG</title>
          <description>Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Elevated Transaminases</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paolo Anderlini, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>mvpacheco@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

